Protagenic Therapeutic is a development stage biopharmaceutical company focusing on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Co.'s proprietary compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Additionally, Co. is engaged in the research and development of follow-on compounds in the TCAP family. Co. is performing clinical trials to obtain Food and Drug Administration approval and commercialization of its product. The PTIX average annual return since 2021 is shown above.
The Average Annual Return on the PTIX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PTIX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PTIX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|